Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 24.25 -3.77% -0.95
KALV closed up 1.12 percent on Thursday, April 15, 2021, on 36 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical KALV trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.77%
Stochastic Buy Signal Bullish -3.77%
Inside Day Range Contraction -3.77%
Wide Bands Range Expansion -3.77%
Oversold Stochastic Weakness -3.77%
180 Bearish Setup Bearish Swing Setup -2.69%
Reversal New Lows Setup Bearish Swing Setup -2.69%
Slingshot Bearish Bearish Swing Setup -2.69%
Outside Day Range Expansion -2.69%
Wide Bands Range Expansion -2.69%
Older End-of-Day Signals for KALV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 2 hours ago
Down 3% about 2 hours ago
Down 2 % about 4 hours ago
Non-ADX 1,2,3,4 Bearish Retracement Entry about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

KalVista Pharmaceuticals, Inc. Description

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Diseases Eye Organ Systems Enzymes Stage Pharmaceutical Macular Edema Diabetic Macular Edema Angioedema Hereditary Angioedema Kallikrein Complement Deficiency C1 Inhibitor Plasma Kallikrein Protease Inhibitor

Is KALV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.0
52 Week Low 9.03
Average Volume 1,295,048
200-Day Moving Average 18.88
50-Day Moving Average 30.41
20-Day Moving Average 27.76
10-Day Moving Average 26.22
Average True Range 1.87
ADX 20.14
+DI 13.67
-DI 23.05
Chandelier Exit (Long, 3 ATRs ) 30.53
Chandelier Exit (Short, 3 ATRs ) 30.17
Upper Bollinger Band 32.95
Lower Bollinger Band 22.57
Percent B (%b) 0.25
BandWidth 37.42
MACD Line -1.39
MACD Signal Line -1.13
MACD Histogram -0.2647
Fundamentals Value
Market Cap 451.15 Million
Num Shares 17.9 Million
EPS -1.38
Price-to-Earnings (P/E) Ratio -18.26
Price-to-Sales 37.26
Price-to-Book 4.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.71
Resistance 3 (R3) 27.81 27.07 27.29
Resistance 2 (R2) 27.07 26.43 27.02 27.15
Resistance 1 (R1) 26.14 26.03 25.77 26.04 27.01
Pivot Point 25.40 25.40 25.21 25.35 25.40
Support 1 (S1) 24.46 24.76 24.09 24.36 23.39
Support 2 (S2) 23.72 24.36 23.67 23.25
Support 3 (S3) 22.79 23.72 23.11
Support 4 (S4) 22.69